The "old" and "current" nuclear medicine imaging in locally advanced breast cancer patient evaluation: 99mTc-MIBI mammoscintigraphy (MMS) and fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT)

被引：0
|
作者：
Evangelista, L. [1 ]
Cervino, A. R. [1 ]
Sanco, R. [1 ]
Memo, L. [1 ]
Burei, M. [1 ]
Michieletto, S. [2 ]
Saibene, T. [2 ]
Valpione, S. [3 ]
Bozza, F. [2 ]
Ghiotto, C. [3 ]
机构：
[1] Ist Oncol Veneto, Nucl Med Unit, Padua, Italy
[2] Ist Oncol Veneto, Surg Oncol Unit, Padua, Italy
[3] Ist Oncol Veneto, Oncol Unit 2, Padua, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2012年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP643
引用
收藏
页码：S284 / S284
页数：1
相关论文
共 50 条
  • [21] Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer
    Yoji YAMAGISHI
    Tomomi KOIWAI
    Tamio YAMASAKI
    Takahiro EINAMA
    Makiko FUKUMURA
    Miyuki HIRATSUKA
    Takako KONO
    Katsumi HAYASHI
    Jiro ISHIDA
    Hideki UENO
    Hitoshi TSUDA
    BMC Cancer, 19
  • [22] The Role of 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) in the Diagnosis and Evaluation of Spondylodiscitis
    Paez, Diana
    Giammarile, Francesco
    Brink, Anita
    Garcia-Perez, Osvaldo
    Estrada-Lobato, Enrique
    SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (03) : 409 - 414
  • [23] The use of [18F]-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) for predicting recurrence in cervical cancer patients
    Brunette, L.
    Mehta, A.
    Lieber, D.
    Bonyadlou, S.
    Lin, Y.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 389 - 389
  • [24] The Role of F-Fluorodeoxyglucose (FDG) Positron Emission Tomography-Computed Tomography (PET/CT) in the Screening of Cervical Cancer: A Literature Review
    Guo, Fengjun
    Yang, Ruiqi
    Tian, Jingyan
    Fan, Limei
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2014, 69 (02) : 197 - 201
  • [25] Evaluation of the effectiveness of the FDG-PET (positron emission tomography)-CT as the preoperative method for the breast cancer
    Futsuhara, K.
    Sakuragi, M.
    Sekine, O.
    Konishi, F.
    EJC SUPPLEMENTS, 2010, 8 (03): : 225 - 225
  • [26] Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience
    Mohammed Shahait
    Ramiz Abu-Hijlih
    Ala’a Farkouh
    Shahed Obeidat
    Samer Salah
    Ahmed Saad Abdlkadir
    Akram Al-Ibraheem
    Journal of the Egyptian National Cancer Institute, 35
  • [27] Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience
    Shahait, Mohammed
    Abu-Hijlih, Ramiz
    Farkouh, Ala'a
    Obeidat, Shahed
    Salah, Samer
    Abdlkadir, Ahmed Saad
    Al-Ibraheem, Akram
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2023, 35 (01)
  • [28] The Role of Positron Emission Tomography/Computed Tomography (PET/CT) for Staging and Disease Response Assessment in Localized and Locally Advanced Pancreatic Cancer
    Ghidini, Michele
    Vuozzo, Marta
    Galassi, Barbara
    Mapelli, Paola
    Ceccarossi, Virginia
    Caccamo, Lucio
    Picchio, Maria
    Dondossola, Daniele
    CANCERS, 2021, 13 (16)
  • [29] Does 18-fluorodeoxyglucose (FDG) uptake by positron emission tomography/computed tomography (PET/CT) predict survival in advanced pancreatic cancer? A single-institution experience
    Ashraf, Noman
    Razzaque, Saqib
    Weber, Jill M.
    Malafa, Mokenge Peter
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [30] Comparison of 18F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (18F-FDG PET/CT) and conventional imaging (CI) for locally advanced breast cancer staging: A prospective study from a tertiary hospital cancer centre in the Western Cape South Africa
    Chilwesa, Paul Mambwe
    CANCER RESEARCH, 2020, 80 (16)
12345